Skip to Content

Rule

New Animal Drugs for Use in Animal Feeds; Decoquinate, Monensin, and Tylosin

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Alpharma, Inc. The NADA provides for use of approved, single-ingredient decoquinate, monensin, and tylosin Type A medicated articles to make three-way combination drug Type B and Type C medicated feeds used for prevention of coccidiosis, improved feed efficiency, and reduction of incidence of liver abscesses in growing-finishing cattle fed in confinement for slaughter.

DATES:

This rule is effective January 10, 2001.

Start Further Info Start Printed Page 1833

FOR FURTHER INFORMATION CONTACT:

Janis R. Messenheimer, Center for Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7578.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Alpharma Inc., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024, filed NADA 141-149 that provides for use of DECCOX® (27.2 gram per pound (g/lb) decoquinate), Rumensin® (20, 30, 45, 60, 80, or 90.7 g/lb monensin activity as monensin sodium) and TYLAN® (10, 40, or 100 g/lb tylosin phosphate) Type A medicated articles to make three-way combination Type B and Type C medicated feeds for use in growing-finishing cattle fed in confinement for slaughter. The Type C medicated feeds contain 13.6 to 27.2 g/ton decoquinate, 5 to 30 g/ton monensin, and 8 to 10 g/ton tylosin, and are used for the prevention of coccidiosis caused by Eimeria bovis and E. zuernii, improved feed efficiency, and reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces pyogenes. The NADA is approved as of November 16, 2000, and the regulations in 21 CFR 558.195 and 558.625 are being amended to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Part 558

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority Start Amendment Part

2. Section 558.195 is amended in the table in paragraph (d) by adding an entry after “Monensin 5 to 30” and before “Chlortetracycline approximately 400” to read as follows:

End Amendment Part
Decoquinate.
* * * * *

(d) * * *

Decoquinate in grams per tonCombination in grams per tonIndications for useLimitationsSponsor
*         *         *         *         *         *         *
Monensin 5 to 30; plus tylosin 8 to 10Cattle fed in confinement for slaughter; for prevention of coccidiosis caused by Eimeria bovis and E. zuernii, improved feed efficiency, and reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces pyogenes.Feed only to cattle fed in confinement for slaughter. Feed continuously as the sole ration to provide 22.7 mg of decoquinate per 100 lb body weight per day, 50 to 360 mg of monensin per head per day, and 60 to 90 mg of tylosin per head per day. Feed at least 28 days during period of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to animals producing milk for food. Also see (c)(1) of this paragraph and § 558.355(d)(8). Monensin as monensin sodium and tylosin as tylosin phosphate provided by 000986 in § 510.600(c) of this chapter.046573
*         *         *         *         *         *         *
Start Printed Page 1834
[Amended]
Start Amendment Part

3. Section 558.355

End Amendment Part Start Amendment Part

4. Section 558.625 is amended by redesignating paragraphs (f)(2)(i) through (f)(2)(v) as (f)(2)(ii) through (f)(2)(vi), and by adding paragraph (f)(2)(i) to read as follows:

End Amendment Part
Tylosin.
* * * * *

(f) * * *

(2) * * *

(i) Decoquinate and monensin as in § 558.195.

* * * * *
Start Signature

Dated: December 26, 2000.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-628 Filed 1-9-01; 8:45 am]

BILLING CODE 4160-01-F